Drug Profile

Lamivudine/zidovudine + nevirapine - Strides Pharma Science

Alternative Names: Zidovudine/lamivudine + nevirapine

Latest Information Update: 03 Dec 2018

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Strides Arcolab
Developer Strides Pharma Science
Class Deoxyribonucleosides; Dideoxynucleosides; Pyrimidine nucleosides; Small interfering RNA
Mechanism of Action Nucleoside reverse transcriptase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

03 Dec 2018 Chemical structure information added
21 Nov 2018 Lamivudine/zidovudine co-packaged with nevirapine is not yet avaliable in USA for HIV-1 infections (Strides website, November 2018)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com